<!DOCTYPE html><html lang="en"><head><title>Help for package UBCRM</title>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
<link href="https://cdnjs.cloudflare.com/ajax/libs/prism/1.29.0/themes/prism.min.css" rel="stylesheet" />
<link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/katex@0.15.3/dist/katex.min.css">
<script type="text/javascript">
const macros = { "\\R": "\\textsf{R}", "\\code": "\\texttt"};
function processMathHTML() {
    var l = document.getElementsByClassName('reqn');
    for (let e of l) { katex.render(e.textContent, e, { throwOnError: false, macros }); }
    return;
}</script>
<script defer src="https://cdn.jsdelivr.net/npm/katex@0.15.3/dist/katex.min.js"
    onload="processMathHTML();"></script>
<link rel="stylesheet" type="text/css" href="R-nav.css" />
</head><body><div class="container"><nav class="package" aria-label="Topic Navigation">
<div class="dropdown-menu">
<h1>Package {UBCRM}</h1>
<h2>Contents</h2>
<ul class="menu">
<li><a href='#UBCRM-package'>
<p>UBCRM is a package containing functions to simulate and conduct dose escalation phase I studies</p></a></li>
<li><a href='#aip'>
<p>Functions to calculate the appropriate dose level singletons</p></a></li>
<li><a href='#CreData'>
<p>Creates a CRM dataframe</p></a></li>
<li><a href='#Crm'>
<p>Dose-escalation with the Continual Reassessment Method</p></a></li>
<li><a href='#fp'><p>Density functions</p></a></li>
<li><a href='#Lp'>
<p>Likelihood functions</p></a></li>
<li><a href='#psip'>
<p>Dose-Toxicity modelisation functions</p></a></li>
<li><a href='#sim3p3'>
<p>Simulation of one dose-escalation study with the classical 3+3 design</p></a></li>
<li><a href='#simCrm'>
<p>Simulation of one dose-escalation study with the Continual Reassessment Method</p></a></li>
<li><a href='#ssim3p3'>
<p>Simulation of n dose-escalation study with the 3+3 design</p></a></li>
<li><a href='#ssimCrm'>
<p>Simulation of n dose-escalation study with the Continual Reassessment Method</p></a></li>
<li><a href='#troisPtrois'>
<p>Dose escalation with the 3+3 design</p></a></li>
<li><a href='#updata'>
<p>Update the CRM dataframe after new patients' collected data</p></a></li>
</ul>
</div>
<hr>
</nav>
<main>
<table role='presentation'>
<tr>
<td>Type:</td>
<td>Package</td>
</tr>
<tr>
<td>Title:</td>
<td>Simulate and Conduct Dose-Escalation Phase I Studies</td>
</tr>
<tr>
<td>Version:</td>
<td>1.0.3</td>
</tr>
<tr>
<td>Date:</td>
<td>2024-04-25</td>
</tr>
<tr>
<td>Author:</td>
<td>Benjamin Esterni with contribution from Baboukar Mane</td>
</tr>
<tr>
<td>Maintainer:</td>
<td>Christophe Zemmour &lt;christophe.zemmour@gmail.com&gt;</td>
</tr>
<tr>
<td>Description:</td>
<td>Two Phase I designs are implemented in the package: the classical 3+3 and the Continual Reassessment Method (&lt;<a href="https://doi.org/10.2307%2F2531628">doi:10.2307/2531628</a>&gt;). Simulations tools are also available to estimate the operating characteristics of the methods with several user-dependent options.</td>
</tr>
<tr>
<td>License:</td>
<td><a href="https://www.r-project.org/Licenses/GPL-2">GPL-2</a> | <a href="https://www.r-project.org/Licenses/GPL-3">GPL-3</a> [expanded from: GPL (&ge; 2)]</td>
</tr>
<tr>
<td>NeedsCompilation:</td>
<td>no</td>
</tr>
<tr>
<td>Packaged:</td>
<td>2024-04-26 08:00:12 UTC; zemmourc</td>
</tr>
<tr>
<td>Repository:</td>
<td>CRAN</td>
</tr>
<tr>
<td>Date/Publication:</td>
<td>2024-04-26 08:30:02 UTC</td>
</tr>
</table>
<hr>
<h2 id='UBCRM-package'>
UBCRM is a package containing functions to simulate and conduct dose escalation phase I studies
</h2><span id='topic+UBCRM-package'></span><span id='topic+UBCRM'></span>

<h3>Description</h3>

<p>Two designs are implemented in the package: the classical 3+3 and the Continual Reassessment Method.
Simulations tools are also available to estimate the operating characteristics of the methods with several user-dependent options.
</p>


<h3>Author(s)</h3>

<p>Benjamin Esterni, Baboukar Mane. Unite de Biostatistique et de Methodologie, Institut Paoli-Calmettes, Marseille, France.
</p>


<h3>References</h3>

<p>O'Quigley J., Pepe M., Fisher L. (1990). Continual Reassessment Method: a practical design for Phase I clinical trials in cancer. Biometrics 46, 33-48. &lt;https://doi.org/10.2307/2531628&gt;
</p>
<p>O'Quigley J., Shen LZ. (1996). Continual Reassessment Method: a likelihood approach. Biometrics 52, 673-684. &lt;https://doi.org/10.2307/2532905&gt;
</p>
<p>Paoletti X., Kramar A. (2009). A comparison of model choices for the Continual Reassessment Method in phase I cancer trials. Statistics in Medecine 28, 3012-3028. &lt;https://doi.org/10.1002/sim.3682&gt;
</p>
<p>Chamorey Emmanuel. (2009). Methodologie des essais de phase precoce en cancerologie: evolution des schemas et apport de la pharmacologie. These.
</p>
<p>Garret-Mayer Elizabeth. (2006). The Continual Reassessment Method for dose-finding studies: a tutorial. Clinical Trials: 57-71. &lt;https://doi.org/10.1191/1740774506cn134oa&gt;
</p>


<h3>Examples</h3>

<pre><code class='language-R'>
data&lt;- CreData(4)
prior&lt;-c(.05,.1,.15,.2)

# One study simulation
simCrm(prior=prior, firstdose = 2, truerate = prior, cohortsize = 3, target = 1/3,
nptmax = 18, nmaxmtd = 6, nmaxdose = 18, sd = 1.34, approach = "bayes", model = "power",
method = "fpost", nextlevel = "ntarget", upskipping = TRUE, downskipping = FALSE,
lastdose = NA, graphic = FALSE, seed = 20130110)

# N simulations with CRM
# Power model, no up skipping, start at dose 2
res1&lt;- ssimCrm(prior=prior, 100, firstdose = 2, truerate = prior, cohortsize = 3,
target = 1/3, nptmax = 18, nmaxmtd = 6, nmaxdose = 18, sd = 1.34, approach = "bayes",
method = "fpost", model = "power", nextlevel = "ntarget", upskipping = TRUE,
downskipping = FALSE, r = 2, seed=20130110)
res1

# Simulations with 3+3 design
res2&lt;- ssim3p3(truerate=prior, 100, r = 2, seed=20130110)
res2
</code></pre>

<hr>
<h2 id='aip'>
Functions to calculate the appropriate dose level singletons
</h2><span id='topic+aip'></span><span id='topic+ail1'></span><span id='topic+ait1'></span><span id='topic+ail2'></span><span id='topic+ait2'></span>

<h3>Description</h3>

<p>Pool of functions to calculate dose level singletons values:
aip, ail2 and ait2 calculate sgl in order that E[psy] = prior,
ail1 and ait1 calculate sgl in order that psy(sgl,1) = prior.
</p>


<h3>Usage</h3>

<pre><code class='language-R'>aip(p_prior, sd = 1.34)
ait1(p_prior, a=1)
ail1(p_prior, a=1)
ait2(p_prior)
ail2(p_prior)
</code></pre>


<h3>Arguments</h3>

<table role = "presentation">
<tr><td><code id="aip_+3A_p_prior">p_prior</code></td>
<td>
<p>Prior toxicity probability.
</p>
</td></tr>
<tr><td><code id="aip_+3A_sd">sd</code></td>
<td>
<p>Standard deviation in case of normal distribution for the parameter.
</p>
</td></tr>
<tr><td><code id="aip_+3A_a">a</code></td>
<td>
<p>Rate in case of exponential distribution for the parameter.
</p>
</td></tr>
</table>


<h3>Value</h3>

<p>Numeric length(p-prior)-vector.
</p>


<h3>Author(s)</h3>

<p>Benjamin Esterni, Baboukar Mane. Unite de Biostatistique et de Methodologie, Institut Paoli-Calmettes, Marseille, France.
</p>


<h3>References</h3>

<p>O'Quigley J., Pepe M., Fisher L. (1990). Continual Reassessment Method: a practical design for Phase I clinical trials in cancer. Biometrics 46, 33-48. &lt;https://doi.org/10.2307/2531628&gt;
</p>
<p>O'Quigley J., Shen LZ. (1996). Continual Reassessment Method: a likelihood approach. Biometrics 52, 673-684. &lt;https://doi.org/10.2307/2532905&gt;
</p>
<p>Paoletti X., Kramar A. (2009). A comparison of model choices for the Continual Reassessment Method in phase I cancer trials. Statistics in Medecine 28, 3012-3028. &lt;https://doi.org/10.1002/sim.3682&gt;
</p>
<p>Chamorey Emmanuel. (2009). Methodologie des essais de phase precoce en cancerologie: evolution des schemas et apport de la pharmacologie. These.
</p>
<p>Garret-Mayer Elizabeth. (2006). The Continual Reassessment Method for dose-finding studies: a tutorial. Clinical Trials: 57-71. &lt;https://doi.org/10.1191/1740774506cn134oa&gt;
</p>

<hr>
<h2 id='CreData'>
Creates a CRM dataframe
</h2><span id='topic+CreData'></span>

<h3>Description</h3>

<p>Creates a n-row summary dataframe indicating the number of treated patients and observed DLTs at each of the n dose-levels. This is the dataframe structure that will be needed in the different functions of the UBCRM package.
</p>


<h3>Usage</h3>

<pre><code class='language-R'>CreData(ndose = 3, dosenames = paste("dose", 1:ndose, sep = " "))
</code></pre>


<h3>Arguments</h3>

<table role = "presentation">
<tr><td><code id="CreData_+3A_ndose">ndose</code></td>
<td>

<p>Number of dose levels.
</p>
</td></tr>
<tr><td><code id="CreData_+3A_dosenames">dosenames</code></td>
<td>

<p>A ndose-length character vector of labels for the dose levels.
</p>
</td></tr>
</table>


<h3>Value</h3>

<p>A ndose * 3 dataframe containing:
</p>
<table role = "presentation">
<tr><td><code>dose</code></td>
<td>
<p>Integer value 1..ndose ordering the doses.</p>
</td></tr>
<tr><td><code>npt</code></td>
<td>
<p>Integer count of the treated patients at dose i.</p>
</td></tr>
<tr><td><code>ndlt</code></td>
<td>
<p>Integer count of the observed DLT at dose i.</p>
</td></tr>
</table>


<h3>Author(s)</h3>

<p>Benjamin Esterni, Baboukar Mane. Unite de Biostatistique et de Methodologie, Institut Paoli-Calmettes, Marseille, France.
</p>


<h3>References</h3>

<p>O'Quigley J., Pepe M., Fisher L. (1990). Continual Reassessment Method: a practical design for Phase I clinical trials in cancer. Biometrics 46, 33-48. &lt;https://doi.org/10.2307/2531628&gt;
</p>
<p>O'Quigley J., Shen LZ. (1996). Continual Reassessment Method: a likelihood approach. Biometrics 52, 673-684. &lt;https://doi.org/10.2307/2532905&gt;
</p>
<p>Paoletti X., Kramar A. (2009). A comparison of model choices for the Continual Reassessment Method in phase I cancer trials. Statistics in Medecine 28, 3012-3028. &lt;https://doi.org/10.1002/sim.3682&gt;
</p>
<p>Chamorey Emmanuel. (2009). Methodologie des essais de phase precoce en cancerologie: evolution des schemas et apport de la pharmacologie. These.
</p>
<p>Garret-Mayer Elizabeth. (2006). The Continual Reassessment Method for dose-finding studies: a tutorial. Clinical Trials: 57-71. &lt;https://doi.org/10.1191/1740774506cn134oa&gt;
</p>


<h3>See Also</h3>

<p><code><a href="#topic+updata">updata</a></code>
</p>


<h3>Examples</h3>

<pre><code class='language-R'>data&lt;- CreData(5,c("5 mg/m2","7 mg/m2","10 mg/m2","15 mg/m2","20 mg/m2"))
data
</code></pre>

<hr>
<h2 id='Crm'>
Dose-escalation with the Continual Reassessment Method
</h2><span id='topic+Crm'></span>

<h3>Description</h3>

<p>The function gives the next level to include patients following a model-based design. Needs an updated input dataframe with the CreData() structure.
</p>


<h3>Usage</h3>

<pre><code class='language-R'>Crm(Dk, prior, target = 1/3, nptmax = 24, nmaxmtd = 6, nmaxdose = nptmax, sd = 1.34,
approach = "bayes", model = "power", method = "fpost", nextlevel = "ntarget",
upskipping = F, downskipping = F, lastdose = NA)
</code></pre>


<h3>Arguments</h3>

<table role = "presentation">
<tr><td><code id="Crm_+3A_dk">Dk</code></td>
<td>

<p>Study dataframe with CreData() structure.
</p>
</td></tr>
<tr><td><code id="Crm_+3A_prior">prior</code></td>
<td>
<p>Numeric vector of prior DLTs probabilities.
</p>
</td></tr>
<tr><td><code id="Crm_+3A_target">target</code></td>
<td>
<p>Target used for the MTD determination.
</p>
</td></tr>
<tr><td><code id="Crm_+3A_nptmax">nptmax</code></td>
<td>
<p>Maximum number of patients to include in the study.
</p>
</td></tr>
<tr><td><code id="Crm_+3A_nmaxmtd">nmaxmtd</code></td>
<td>
<p>Maximum number of patients to be treated at the designated MTD. Assign a high value (=nptmax) to avoid such a stopping rule.
</p>
</td></tr>
<tr><td><code id="Crm_+3A_nmaxdose">nmaxdose</code></td>
<td>
<p>Maximum number of patients to be treated at the same dose. Assign a high value (=nptmax) to avoid such a stopping rule.
</p>
</td></tr>
<tr><td><code id="Crm_+3A_sd">sd</code></td>
<td>
<p>Standard deviation used in case of a normal distribution assumption for the parameter.
</p>
</td></tr>
<tr><td><code id="Crm_+3A_approach">approach</code></td>
<td>
<p>Character indicating the estimation method: &quot;bayes&quot; (default value) for CRM or &quot;mle&quot; for CRML.
</p>
</td></tr>
<tr><td><code id="Crm_+3A_model">model</code></td>
<td>
<p>Character indicating the dose-DLT relationship model: &quot;power&quot;, &quot;tangent&quot; or &quot;logistic&quot;. More informations in the details section.
</p>
</td></tr>
<tr><td><code id="Crm_+3A_method">method</code></td>
<td>
<p>Estimation method for the posterior probabilities. &quot;fpost&quot; (default) estimates the mean of the posterior distribution of the parameter alpha (hat_alpha=E[alpha]) and uses it in psy(hat_alpha,...). &quot;ppostp&quot; and &quot;pposts&quot; directly estimate the mean of the posterior DLT probability. &quot;ppostp&quot; uses prior as singletons whereas &quot;pposts&quot; calculates appropriates singletons (see ail, ait or aip functions).
</p>
</td></tr>
<tr><td><code id="Crm_+3A_nextlevel">nextlevel</code></td>
<td>
<p>Character option used for determining the next dose level. &quot;ntarget&quot; (default) if the next level is chosen as the closest level to the desired target (may be higher than target). &quot;utarget&quot; if the next level is the closest level with the restriction to be lower than the target value.
</p>
</td></tr>
<tr><td><code id="Crm_+3A_upskipping">upskipping</code></td>
<td>
<p>Boolean option used for determining the next dose level. If TRUE no level skip in escalation will be allowed. If FALSE (default) the level skips will be permitted.
</p>
</td></tr>
<tr><td><code id="Crm_+3A_downskipping">downskipping</code></td>
<td>
<p>Boolean option used for determining the next dose level. If TRUE no level skip in desescalation will be allowed. If FALSE (default) the level skips will be permitted.
</p>
</td></tr>
<tr><td><code id="Crm_+3A_lastdose">lastdose</code></td>
<td>
<p>Integer representing the last experimented dose level.
</p>
</td></tr>
</table>


<h3>Details</h3>

<p>Details of the 3 dose-DLT relationship proposed models:
&quot;power&quot; for the power model psy(s,a)=s^exp(a),
&quot;tangent&quot; for the hyperbolic tangent model psy(s,a)= ((tanh(s)+1)/2)**a,
&quot;logistic&quot; for the logistic model psy(s,a) = exp(3+a*s)/(1+exp(3+a*s)).
Note: power and tangent models are equivalent after an appropriate transformation on the parameter.
</p>


<h3>Value</h3>

<table role = "presentation">
<tr><td><code>nextdose</code></td>
<td>
<p>An integer representing the next recommended dose to experiment.</p>
</td></tr>
<tr><td><code>mtd</code></td>
<td>
<p>If reached, an integer representing the MTD.</p>
</td></tr>
<tr><td><code>prob</code></td>
<td>
<p>Posterior DLTs probabilities.</p>
</td></tr>
</table>


<h3>Author(s)</h3>

<p>Benjamin Esterni, Baboukar Mane. Unite de Biostatistique et de Methodologie, Institut Paoli-Calmettes, Marseille, France.
</p>


<h3>References</h3>

<p>O'Quigley J., Pepe M., Fisher L. (1990). Continual Reassessment Method: a practical design for Phase I clinical trials in cancer. Biometrics 46, 33-48. &lt;https://doi.org/10.2307/2531628&gt;
</p>
<p>O'Quigley J., Shen LZ. (1996). Continual Reassessment Method: a likelihood approach. Biometrics 52, 673-684. &lt;https://doi.org/10.2307/2532905&gt;
</p>
<p>Paoletti X., Kramar A. (2009). A comparison of model choices for the Continual Reassessment Method in phase I cancer trials. Statistics in Medecine 28, 3012-3028. &lt;https://doi.org/10.1002/sim.3682&gt;
</p>
<p>Chamorey Emmanuel. (2009). Methodologie des essais de phase precoce en cancerologie: evolution des schemas et apport de la pharmacologie. These.
</p>
<p>Garret-Mayer Elizabeth. (2006). The Continual Reassessment Method for dose-finding studies: a tutorial. Clinical Trials: 57-71. &lt;https://doi.org/10.1191/1740774506cn134oa&gt;
</p>


<h3>See Also</h3>

<p><code><a href="#topic+simCrm">simCrm</a></code>, <code><a href="#topic+ssimCrm">ssimCrm</a></code>
</p>


<h3>Examples</h3>

<pre><code class='language-R'>data&lt;- CreData(5)
data&lt;- updata(data,1,3,0)
data&lt;- updata(data,2,3,1)
data&lt;- updata(data,2,3,1)
data
Crm(data,prior=c(0.1,0.15,0.25,0.35,0.45),target=0.3,nextlevel="ntarget",nptmax=24,nmaxmtd=6)
data&lt;- updata(data,3,3,2)
data
Crm(data,prior=c(0.1,0.15,0.25,0.35,0.45),target=0.3,nextlevel="ntarget",nptmax=24,nmaxmtd=6)
</code></pre>

<hr>
<h2 id='fp'>Density functions
</h2><span id='topic+fp'></span><span id='topic+ft'></span><span id='topic+fl'></span>

<h3>Description</h3>

<p>Density functions for the model parameter.
fp(a,sd) is the normal density: 1/(sd*sqrt(2*pi))*exp(-(a^2)/(2*sd^2)).
ft and fl are the exponential density (with a fixed rate = 1): exp(-a).
</p>


<h3>Usage</h3>

<pre><code class='language-R'>fp(a, sd)
ft(a)
fl(a)
</code></pre>


<h3>Arguments</h3>

<table role = "presentation">
<tr><td><code id="fp_+3A_a">a</code></td>
<td>
<p>Parameter.
</p>
</td></tr>
<tr><td><code id="fp_+3A_sd">sd</code></td>
<td>
<p>Standard deviation.
</p>
</td></tr>
</table>


<h3>Value</h3>

<p>Numeric value of the computed density.
</p>


<h3>Author(s)</h3>

<p>Benjamin Esterni, Baboukar Mane. Unite de Biostatistique et de Methodologie, Institut Paoli-Calmettes, Marseille, France.
</p>


<h3>References</h3>

<p>O'Quigley J., Pepe M., Fisher L. (1990). Continual Reassessment Method: a practical design for Phase I clinical trials in cancer. Biometrics 46, 33-48. &lt;https://doi.org/10.2307/2531628&gt;
</p>
<p>O'Quigley J., Shen LZ. (1996). Continual Reassessment Method: a likelihood approach. Biometrics 52, 673-684. &lt;https://doi.org/10.2307/2532905&gt;
</p>
<p>Paoletti X., Kramar A. (2009). A comparison of model choices for the Continual Reassessment Method in phase I cancer trials. Statistics in Medecine 28, 3012-3028. &lt;https://doi.org/10.1002/sim.3682&gt;
</p>
<p>Chamorey Emmanuel. (2009). Methodologie des essais de phase precoce en cancerologie: evolution des schemas et apport de la pharmacologie. These.
</p>
<p>Garret-Mayer Elizabeth. (2006). The Continual Reassessment Method for dose-finding studies: a tutorial. Clinical Trials: 57-71. &lt;https://doi.org/10.1191/1740774506cn134oa&gt;
</p>

<hr>
<h2 id='Lp'>
Likelihood functions
</h2><span id='topic+Lp'></span><span id='topic+Lt'></span><span id='topic+Ll'></span>

<h3>Description</h3>

<p>Lp is the likelihood function for the power model psy(s,a)=s^exp(a).
Lt is the likelihood function for the hyperbolic tangent model psy(s,a)= ((tanh(s)+1)/2)**a.
Ll is the likelihood function for the logistic model psy(s,a) = exp(3+a*s)/(1+exp(3+a*s)).
</p>


<h3>Usage</h3>

<pre><code class='language-R'>Lp(a, data, sgl)
Lt(a, data, sgl)
Ll(a, data, sgl)
</code></pre>


<h3>Arguments</h3>

<table role = "presentation">
<tr><td><code id="Lp_+3A_a">a</code></td>
<td>
<p>Parameter.
</p>
</td></tr>
<tr><td><code id="Lp_+3A_data">data</code></td>
<td>
<p>CRM dataframe with a CreData() structure.
</p>
</td></tr>
<tr><td><code id="Lp_+3A_sgl">sgl</code></td>
<td>
<p>Dose level singleton.
</p>
</td></tr>
</table>


<h3>Value</h3>

<p>Numeric value of the computed likelihood.
</p>


<h3>Author(s)</h3>

<p>Benjamin Esterni, Baboukar Mane. Unite de Biostatistique et de Methodologie, Institut Paoli-Calmettes, Marseille, France.
</p>


<h3>References</h3>

<p>O'Quigley J., Pepe M., Fisher L. (1990). Continual Reassessment Method: a practical design for Phase I clinical trials in cancer. Biometrics 46, 33-48. &lt;https://doi.org/10.2307/2531628&gt;
</p>
<p>O'Quigley J., Shen LZ. (1996). Continual Reassessment Method: a likelihood approach. Biometrics 52, 673-684. &lt;https://doi.org/10.2307/2532905&gt;
</p>
<p>Paoletti X., Kramar A. (2009). A comparison of model choices for the Continual Reassessment Method in phase I cancer trials. Statistics in Medecine 28, 3012-3028. &lt;https://doi.org/10.1002/sim.3682&gt;
</p>
<p>Chamorey Emmanuel. (2009). Methodologie des essais de phase precoce en cancerologie: evolution des schemas et apport de la pharmacologie. These.
</p>
<p>Garret-Mayer Elizabeth. (2006). The Continual Reassessment Method for dose-finding studies: a tutorial. Clinical Trials: 57-71. &lt;https://doi.org/10.1191/1740774506cn134oa&gt;
</p>

<hr>
<h2 id='psip'>
Dose-Toxicity modelisation functions
</h2><span id='topic+psip'></span><span id='topic+psit'></span><span id='topic+psil'></span>

<h3>Description</h3>

<p>psip corresponds to the power model psy(s,a)=s^exp(a).
psit corresponds to the  hyperbolic tangent model psy(s,a)= ((tanh(s)+1)/2)**a.
psil corresponds to the  logistic model psy(s,a) = exp(3+a*s)/(1+exp(3+a*s)).
</p>


<h3>Usage</h3>

<pre><code class='language-R'>psip(sgl,a)
psit(sgl,a)
psil(sgl,a)
</code></pre>


<h3>Arguments</h3>

<table role = "presentation">
<tr><td><code id="psip_+3A_sgl">sgl</code></td>
<td>
<p>Dose level singleton.
</p>
</td></tr>
<tr><td><code id="psip_+3A_a">a</code></td>
<td>
<p>Parameter.
</p>
</td></tr>
</table>


<h3>Value</h3>

<p>Numeric value of the computed function.
</p>


<h3>Author(s)</h3>

<p>Benjamin Esterni, Baboukar Mane. Unite de Biostatistique et de Methodologie, Institut Paoli-Calmettes, Marseille, France.
</p>


<h3>References</h3>

<p>O'Quigley J., Pepe M., Fisher L. (1990). Continual Reassessment Method: a practical design for Phase I clinical trials in cancer. Biometrics 46, 33-48. &lt;https://doi.org/10.2307/2531628&gt;
</p>
<p>O'Quigley J., Shen LZ. (1996). Continual Reassessment Method: a likelihood approach. Biometrics 52, 673-684. &lt;https://doi.org/10.2307/2532905&gt;
</p>
<p>Paoletti X., Kramar A. (2009). A comparison of model choices for the Continual Reassessment Method in phase I cancer trials. Statistics in Medecine 28, 3012-3028. &lt;https://doi.org/10.1002/sim.3682&gt;
</p>
<p>Chamorey Emmanuel. (2009). Methodologie des essais de phase precoce en cancerologie: evolution des schemas et apport de la pharmacologie. These.
</p>
<p>Garret-Mayer Elizabeth. (2006). The Continual Reassessment Method for dose-finding studies: a tutorial. Clinical Trials: 57-71. &lt;https://doi.org/10.1191/1740774506cn134oa&gt;
</p>

<hr>
<h2 id='sim3p3'>
Simulation of one dose-escalation study with the classical 3+3 design
</h2><span id='topic+sim3p3'></span>

<h3>Description</h3>

<p>Given a true rates vector of DLT probabilities, the function simulate a 3+3 dose-escalation design.
</p>


<h3>Usage</h3>

<pre><code class='language-R'>sim3p3(truerate, seed = NULL)
</code></pre>


<h3>Arguments</h3>

<table role = "presentation">
<tr><td><code id="sim3p3_+3A_truerate">truerate</code></td>
<td>
<p>A nlevel-length vector of true rates for the DLTs.
</p>
</td></tr>
<tr><td><code id="sim3p3_+3A_seed">seed</code></td>
<td>
<p>If not empty, the seed to use for random generation.
</p>
</td></tr>
</table>


<h3>Value</h3>

<table role = "presentation">
<tr><td><code>data</code></td>
<td>
<p>Study data.</p>
</td></tr>
<tr><td><code>mtd</code></td>
<td>
<p>If reached, an integer representing the MTD level.</p>
</td></tr>
<tr><td><code>lastdose</code></td>
<td>
<p>An integer representing the last experimented dose.</p>
</td></tr>
</table>


<h3>Author(s)</h3>

<p>Benjamin Esterni, Baboukar Mane. Unite de Biostatistique et de Methodologie, Institut Paoli-Calmettes, Marseille, France.
</p>


<h3>References</h3>

<p>O'Quigley J., Pepe M., Fisher L. (1990). Continual Reassessment Method: a practical design for Phase I clinical trials in cancer. Biometrics 46, 33-48. &lt;https://doi.org/10.2307/2531628&gt;
</p>
<p>O'Quigley J., Shen LZ. (1996). Continual Reassessment Method: a likelihood approach. Biometrics 52, 673-684. &lt;https://doi.org/10.2307/2532905&gt;
</p>
<p>Paoletti X., Kramar A. (2009). A comparison of model choices for the Continual Reassessment Method in phase I cancer trials. Statistics in Medecine 28, 3012-3028. &lt;https://doi.org/10.1002/sim.3682&gt;
</p>
<p>Chamorey Emmanuel. (2009). Methodologie des essais de phase precoce en cancerologie: evolution des schemas et apport de la pharmacologie. These.
</p>
<p>Garret-Mayer Elizabeth. (2006). The Continual Reassessment Method for dose-finding studies: a tutorial. Clinical Trials: 57-71. &lt;https://doi.org/10.1191/1740774506cn134oa&gt;
</p>


<h3>See Also</h3>

<p><code><a href="#topic+troisPtrois">troisPtrois</a></code>, <code><a href="#topic+ssim3p3">ssim3p3</a></code>
</p>


<h3>Examples</h3>

<pre><code class='language-R'># A 3-dose study with 10%, 20% and 30% of true rates for toxicity
sim3p3(c(0.1,0.2,0.3))
</code></pre>

<hr>
<h2 id='simCrm'>
Simulation of one dose-escalation study with the Continual Reassessment Method
</h2><span id='topic+simCrm'></span>

<h3>Description</h3>

<p>Given prior and true rates vectors of DLT probabilities, the function simulates a CRM dose-escalation design.
</p>


<h3>Usage</h3>

<pre><code class='language-R'>simCrm(prior, firstdose = NA, truerate = prior, cohortsize = 3, target = 1/3,nptmax = 24,
nmaxmtd = nptmax, nmaxdose = nptmax, sd = 1.34, approach = "bayes", model = "power",
method = "fpost", nextlevel = "ntarget", upskipping = F, downskipping = F, lastdose = NA,
graphic = F, seed = NULL)
</code></pre>


<h3>Arguments</h3>

<table role = "presentation">
<tr><td><code id="simCrm_+3A_prior">prior</code></td>
<td>
<p>Numeric vector of prior DLT probabilities.
</p>
</td></tr>
<tr><td><code id="simCrm_+3A_firstdose">firstdose</code></td>
<td>
<p>Integer representing the dose at which the first cohort will be treated.
</p>
</td></tr>
<tr><td><code id="simCrm_+3A_truerate">truerate</code></td>
<td>
<p>A nlevel-length vector of true rates for the DLTs.
</p>
</td></tr>
<tr><td><code id="simCrm_+3A_cohortsize">cohortsize</code></td>
<td>
<p>Size of the cohort. Default value = 3.
</p>
</td></tr>
<tr><td><code id="simCrm_+3A_target">target</code></td>
<td>
<p>Target used for the MTD determination.
</p>
</td></tr>
<tr><td><code id="simCrm_+3A_nptmax">nptmax</code></td>
<td>
<p>Maximum number of patients to include in the study.
</p>
</td></tr>
<tr><td><code id="simCrm_+3A_nmaxmtd">nmaxmtd</code></td>
<td>
<p>Maximum number of patients to be treated at the designated MTD. Assign a high value (=nptmax) to avoid such a stopping rule.
</p>
</td></tr>
<tr><td><code id="simCrm_+3A_nmaxdose">nmaxdose</code></td>
<td>
<p>Maximum number of patients to be treated at the same dose. Assign a high value (=nptmax) to avoid such a stopping rule.
</p>
</td></tr>
<tr><td><code id="simCrm_+3A_sd">sd</code></td>
<td>
<p>Standard deviation used in case of a normal distribution assumption for the parameter.
</p>
</td></tr>
<tr><td><code id="simCrm_+3A_approach">approach</code></td>
<td>
<p>Character indicating the estimation method: &quot;bayes&quot; (default value) for CRM or &quot;mle&quot; for CRML.
</p>
</td></tr>
<tr><td><code id="simCrm_+3A_model">model</code></td>
<td>
<p>Character indicating the dose-DLT relationship model: &quot;power&quot;, &quot;tangent&quot; or &quot;logistic&quot;.
</p>
</td></tr>
<tr><td><code id="simCrm_+3A_method">method</code></td>
<td>
<p>Estimation method for the posterior probabilities. &quot;fpost&quot; (default) estimates the mean of the posterior distribution of the paramater alpha (hat_alpha=E[alpha]) and uses it in psy(hat_alpha,...). &quot;ppostp&quot; and &quot;pposts&quot; directly estimate the mean of the posterior DLT probability. &quot;ppostp&quot; uses prior as singletons whereas &quot;pposts&quot; calculates appropriate singletons (see ail, ait or aip functions).
</p>
</td></tr>
<tr><td><code id="simCrm_+3A_nextlevel">nextlevel</code></td>
<td>
<p>Character option used for determining the next dose level. &quot;ntarget&quot; (default) if the next level is chosen as the closest level to the desired target (may be higher than target). &quot;utarget&quot; if the next level is the closest level with the restriction to be lower than the target value.
</p>
</td></tr>
<tr><td><code id="simCrm_+3A_upskipping">upskipping</code></td>
<td>
<p>Boolean option used for determining the next dose level. If TRUE no level skip in escalation will be allowed. If FALSE (default) the level skips will be permitted.
</p>
</td></tr>
<tr><td><code id="simCrm_+3A_downskipping">downskipping</code></td>
<td>
<p>Boolean option used for determining the next dose level. If TRUE no level skip in desescalation will be allowed. If FALSE (default) the level skips will be permitted.
</p>
</td></tr>
<tr><td><code id="simCrm_+3A_lastdose">lastdose</code></td>
<td>
<p>Integer representing the last experimented dose level.
</p>
</td></tr>
<tr><td><code id="simCrm_+3A_graphic">graphic</code></td>
<td>
<p>Boolean option for graphic generation.
</p>
</td></tr>
<tr><td><code id="simCrm_+3A_seed">seed</code></td>
<td>
<p>If not empty, the seed to use for random generation.
</p>
</td></tr>
</table>


<h3>Value</h3>

<table role = "presentation">
<tr><td><code>data</code></td>
<td>
<p>Study data.</p>
</td></tr>
<tr><td><code>dose</code></td>
<td>
<p>Integer vector representing for each cohort the experimented dose levels.</p>
</td></tr>
<tr><td><code>nDLT</code></td>
<td>
<p>Integer vector representing for each cohort the number of observed DLTs.</p>
</td></tr>
<tr><td><code>mtd</code></td>
<td>
<p>If reached, an integer representing the MTD level.</p>
</td></tr>
<tr><td><code>lastdose</code></td>
<td>
<p>An integer representing the last experimented dose.</p>
</td></tr>
<tr><td><code>prob</code></td>
<td>
<p>Posterior DLT probabilities.</p>
</td></tr>
</table>


<h3>Author(s)</h3>

<p>Benjamin Esterni, Baboukar Mane. Unite de Biostatistique et de Methodologie, Institut Paoli-Calmettes, Marseille, France.
</p>


<h3>References</h3>

<p>O'Quigley J., Pepe M., Fisher L. (1990). Continual Reassessment Method: a practical design for Phase I clinical trials in cancer. Biometrics 46, 33-48. &lt;https://doi.org/10.2307/2531628&gt;
</p>
<p>O'Quigley J., Shen LZ. (1996). Continual Reassessment Method: a likelihood approach. Biometrics 52, 673-684. &lt;https://doi.org/10.2307/2532905&gt;
</p>
<p>Paoletti X., Kramar A. (2009). A comparison of model choices for the Continual Reassessment Method in phase I cancer trials. Statistics in Medecine 28, 3012-3028. &lt;https://doi.org/10.1002/sim.3682&gt;
</p>
<p>Chamorey Emmanuel. (2009). Methodologie des essais de phase precoce en cancerologie: evolution des schemas et apport de la pharmacologie. These.
</p>
<p>Garret-Mayer Elizabeth. (2006). The Continual Reassessment Method for dose-finding studies: a tutorial. Clinical Trials: 57-71. &lt;https://doi.org/10.1191/1740774506cn134oa&gt;
</p>


<h3>See Also</h3>

<p><code><a href="#topic+Crm">Crm</a></code>, <code><a href="#topic+ssimCrm">ssimCrm</a></code>
</p>


<h3>Examples</h3>

<pre><code class='language-R'>simCrm(c(0.1,0.2,0.3,0.35,0.45),firstdose=1,target=0.33)
</code></pre>

<hr>
<h2 id='ssim3p3'>
Simulation of n dose-escalation study with the 3+3 design
</h2><span id='topic+ssim3p3'></span>

<h3>Description</h3>

<p>The ssim3p3 function simulates n dose-escalation study with the 3+3 design and provides summarized results.
</p>


<h3>Usage</h3>

<pre><code class='language-R'>ssim3p3(truerate, n, r = 2, seed = NULL)
</code></pre>


<h3>Arguments</h3>

<table role = "presentation">
<tr><td><code id="ssim3p3_+3A_truerate">truerate</code></td>
<td>
<p>A nlevel-length vector of true rates for the DLTs.
</p>
</td></tr>
<tr><td><code id="ssim3p3_+3A_n">n</code></td>
<td>
<p>Number of studies to simulate.
</p>
</td></tr>
<tr><td><code id="ssim3p3_+3A_r">r</code></td>
<td>
<p>Integer, number of digits for percentages in output.
</p>
</td></tr>
<tr><td><code id="ssim3p3_+3A_seed">seed</code></td>
<td>
<p>If not empty, the seed to use for random generation.
</p>
</td></tr>
</table>


<h3>Value</h3>

<table role = "presentation">
<tr><td><code>data</code></td>
<td>
<p>Summarized result in a &quot;np1&quot; view.</p>
</td></tr>
<tr><td><code>norecommendation</code></td>
<td>
<p>Percentage of studies with no recommendation for the MTD (in case of the first level is considered as toxic).</p>
</td></tr>
<tr><td><code>mean.npt</code></td>
<td>
<p>Mean number of enrolled patients.</p>
</td></tr>
<tr><td><code>mean.ndlt</code></td>
<td>
<p>Mean number of observed DLTs.</p>
</td></tr>
<tr><td><code>mean.lastdose</code></td>
<td>
<p>Mean last experimented dose level.</p>
</td></tr>
</table>


<h3>Author(s)</h3>

<p>Benjamin Esterni, Baboukar Mane. Unite de Biostatistique et de Methodologie, Institut Paoli-Calmettes, Marseille, France.
</p>


<h3>References</h3>

<p>O'Quigley J., Pepe M., Fisher L. (1990). Continual Reassessment Method: a practical design for Phase I clinical trials in cancer. Biometrics 46, 33-48. &lt;https://doi.org/10.2307/2531628&gt;
</p>
<p>O'Quigley J., Shen LZ. (1996). Continual Reassessment Method: a likelihood approach. Biometrics 52, 673-684. &lt;https://doi.org/10.2307/2532905&gt;
</p>
<p>Paoletti X., Kramar A. (2009). A comparison of model choices for the Continual Reassessment Method in phase I cancer trials. Statistics in Medecine 28, 3012-3028. &lt;https://doi.org/10.1002/sim.3682&gt;
</p>
<p>Chamorey Emmanuel. (2009). Methodologie des essais de phase precoce en cancerologie: evolution des schemas et apport de la pharmacologie. These.
</p>
<p>Garret-Mayer Elizabeth. (2006). The Continual Reassessment Method for dose-finding studies: a tutorial. Clinical Trials: 57-71. &lt;https://doi.org/10.1191/1740774506cn134oa&gt;
</p>


<h3>See Also</h3>

<p><code><a href="#topic+troisPtrois">troisPtrois</a></code>, <code><a href="#topic+sim3p3">sim3p3</a></code>
</p>


<h3>Examples</h3>

<pre><code class='language-R'>ssim3p3(c(0.1,0.2,0.25,0.35),100)
</code></pre>

<hr>
<h2 id='ssimCrm'>
Simulation of n dose-escalation study with the Continual Reassessment Method
</h2><span id='topic+ssimCrm'></span>

<h3>Description</h3>

<p>The ssimCrm function simulates n dose-escalation study with the CRM and provides summarized results.
</p>


<h3>Usage</h3>

<pre><code class='language-R'>ssimCrm(prior, n, firstdose = NA, truerate = prior, cohortsize = 3, target = 1/3,
nptmax = 24, nmaxmtd = nptmax, nmaxdose = nptmax, sd = 1.34, approach = "bayes",
method = "fpost", model = "power", nextlevel = "ntarget", upskipping = F,
downskipping = F, r = 2, seed = NULL)
</code></pre>


<h3>Arguments</h3>

<table role = "presentation">
<tr><td><code id="ssimCrm_+3A_prior">prior</code></td>
<td>
<p>Numeric vector of prior DLT probabilities.
</p>
</td></tr>
<tr><td><code id="ssimCrm_+3A_n">n</code></td>
<td>
<p>Number of studies to simulate.
</p>
</td></tr>
<tr><td><code id="ssimCrm_+3A_firstdose">firstdose</code></td>
<td>
<p>Integer representing the dose at which the first cohort will be treated.
</p>
</td></tr>
<tr><td><code id="ssimCrm_+3A_truerate">truerate</code></td>
<td>
<p>A nlevel-length vector of true rates for the DLTs.
</p>
</td></tr>
<tr><td><code id="ssimCrm_+3A_cohortsize">cohortsize</code></td>
<td>
<p>Size of the cohort. Default value = 3.
</p>
</td></tr>
<tr><td><code id="ssimCrm_+3A_target">target</code></td>
<td>
<p>Target used for the MTD determination.
</p>
</td></tr>
<tr><td><code id="ssimCrm_+3A_nptmax">nptmax</code></td>
<td>
<p>Maximum number of patients to include in the study.
</p>
</td></tr>
<tr><td><code id="ssimCrm_+3A_nmaxmtd">nmaxmtd</code></td>
<td>
<p>Maximum number of patients to be treated at the designated MTD. Assign a high value (=nptmax) to avoid such a stopping rule.
</p>
</td></tr>
<tr><td><code id="ssimCrm_+3A_nmaxdose">nmaxdose</code></td>
<td>
<p>Maximum number of patients to be treated at the same dose. Assign a high value (=nptmax) to avoid such a stopping rule.
</p>
</td></tr>
<tr><td><code id="ssimCrm_+3A_sd">sd</code></td>
<td>
<p>Standard deviation used in case of a normal distribution assumption for the parameter.
</p>
</td></tr>
<tr><td><code id="ssimCrm_+3A_approach">approach</code></td>
<td>
<p>Character indicating the estimation method: &quot;bayes&quot; (default value) for CRM or &quot;mle&quot; for CRML.
</p>
</td></tr>
<tr><td><code id="ssimCrm_+3A_model">model</code></td>
<td>
<p>Character indicating the dose-DLT relationship model: &quot;power&quot;, &quot;tangent&quot; or &quot;logistic&quot;.
</p>
</td></tr>
<tr><td><code id="ssimCrm_+3A_method">method</code></td>
<td>
<p>Estimation method for the posterior probabilities. &quot;fpost&quot; (default) estimates the mean of the posterior distribution of the paramater alpha (hat_alpha=E[alpha]) and uses it in psy(hat_alpha,...). &quot;ppostp&quot; and &quot;pposts&quot; directly estimate the mean of the posterior DLT probability. &quot;ppostp&quot; uses prior as singletons whereas &quot;pposts&quot; calculates appropriate singletons (see ail, ait or aip functions).
</p>
</td></tr>
<tr><td><code id="ssimCrm_+3A_nextlevel">nextlevel</code></td>
<td>
<p>Character option used for determining the next dose level. &quot;ntarget&quot; (default) if the next level is chosen as the closest level to the desired target (may be higher than target). &quot;utarget&quot; if the next level is the closest level with the restriction to be lower than the target value.
</p>
</td></tr>
<tr><td><code id="ssimCrm_+3A_upskipping">upskipping</code></td>
<td>
<p>Boolean option used for determining the next dose level. If TRUE no level skip in escalation will be allowed. If FALSE (default) the level skips will be permitted.
</p>
</td></tr>
<tr><td><code id="ssimCrm_+3A_downskipping">downskipping</code></td>
<td>
<p>Boolean option used for determining the next dose level. If TRUE no level skip in desescalation will be allowed. If FALSE (default) the level skips will be permitted.
</p>
</td></tr>
<tr><td><code id="ssimCrm_+3A_r">r</code></td>
<td>
<p>Integer, number of digits for percentages in output.
</p>
</td></tr>
<tr><td><code id="ssimCrm_+3A_seed">seed</code></td>
<td>
<p>If not empty, the seed to use for random generation.
</p>
</td></tr>
</table>


<h3>Value</h3>

<table role = "presentation">
<tr><td><code>data</code></td>
<td>
<p>Summarized result in a &quot;np1&quot; view.</p>
</td></tr>
<tr><td><code>norecommendation</code></td>
<td>
<p>Percentage of studies with no recommendation for the MTD (in case of the first level is considered as toxic).</p>
</td></tr>
<tr><td><code>mean.npt</code></td>
<td>
<p>Mean number of enrolled patients.</p>
</td></tr>
<tr><td><code>mean.ndlt</code></td>
<td>
<p>Mean number of observed DLTs.</p>
</td></tr>
<tr><td><code>mean.lastdose</code></td>
<td>
<p>Mean last experimented dose level.</p>
</td></tr>
<tr><td><code>mean.prob</code></td>
<td>
<p>Mean of posterior DLT probabilities.</p>
</td></tr>
</table>


<h3>Author(s)</h3>

<p>Benjamin Esterni, Baboukar Mane. Unite de Biostatistique et de Methodologie, Institut Paoli-Calmettes, Marseille, France.
</p>


<h3>References</h3>

<p>O'Quigley J., Pepe M., Fisher L. (1990). Continual Reassessment Method: a practical design for Phase I clinical trials in cancer. Biometrics 46, 33-48. &lt;https://doi.org/10.2307/2531628&gt;
</p>
<p>O'Quigley J., Shen LZ. (1996). Continual Reassessment Method: a likelihood approach. Biometrics 52, 673-684. &lt;https://doi.org/10.2307/2532905&gt;
</p>
<p>Paoletti X., Kramar A. (2009). A comparison of model choices for the Continual Reassessment Method in phase I cancer trials. Statistics in Medecine 28, 3012-3028. &lt;https://doi.org/10.1002/sim.3682&gt;
</p>
<p>Chamorey Emmanuel. (2009). Methodologie des essais de phase precoce en cancerologie: evolution des schemas et apport de la pharmacologie. These.
</p>
<p>Garret-Mayer Elizabeth. (2006). The Continual Reassessment Method for dose-finding studies: a tutorial. Clinical Trials: 57-71. &lt;https://doi.org/10.1191/1740774506cn134oa&gt;
</p>


<h3>See Also</h3>

<p><code><a href="#topic+Crm">Crm</a></code>, <code><a href="#topic+simCrm">simCrm</a></code>
</p>


<h3>Examples</h3>

<pre><code class='language-R'>ssimCrm(c(0.1,0.2,0.3,0.35,0.45),firstdose=1,target=0.33,n=100)
</code></pre>

<hr>
<h2 id='troisPtrois'>
Dose escalation with the 3+3 design
</h2><span id='topic+troisPtrois'></span>

<h3>Description</h3>

<p>The function gives the next level to include patients following a 3+3 design. Needs an updated input dataframe with the CreData() structure.
</p>


<h3>Usage</h3>

<pre><code class='language-R'>troisPtrois(data = data, lastdose)
</code></pre>


<h3>Arguments</h3>

<table role = "presentation">
<tr><td><code id="troisPtrois_+3A_data">data</code></td>
<td>

<p>Study dataframe with CreData() structure.
</p>
</td></tr>
<tr><td><code id="troisPtrois_+3A_lastdose">lastdose</code></td>
<td>

<p>Integer representing the last experimented dose level.
</p>
</td></tr>
</table>


<h3>Value</h3>

<table role = "presentation">
<tr><td><code>nextdose</code></td>
<td>
<p>An integer representing the next recommended dose to experiment.</p>
</td></tr>
<tr><td><code>mtd</code></td>
<td>
<p>If reached, an integer representing the MTD.</p>
</td></tr>
</table>


<h3>Author(s)</h3>

<p>Benjamin Esterni, Baboukar Mane. Unite de Biostatistique et de Methodologie, Institut Paoli-Calmettes, Marseille, France.
</p>


<h3>References</h3>

<p>O'Quigley J., Pepe M., Fisher L. (1990). Continual Reassessment Method: a practical design for Phase I clinical trials in cancer. Biometrics 46, 33-48. &lt;https://doi.org/10.2307/2531628&gt;
</p>
<p>O'Quigley J., Shen LZ. (1996). Continual Reassessment Method: a likelihood approach. Biometrics 52, 673-684. &lt;https://doi.org/10.2307/2532905&gt;
</p>
<p>Paoletti X., Kramar A. (2009). A comparison of model choices for the Continual Reassessment Method in phase I cancer trials. Statistics in Medecine 28, 3012-3028. &lt;https://doi.org/10.1002/sim.3682&gt;
</p>
<p>Chamorey Emmanuel. (2009). Methodologie des essais de phase precoce en cancerologie: evolution des schemas et apport de la pharmacologie. These.
</p>
<p>Garret-Mayer Elizabeth. (2006). The Continual Reassessment Method for dose-finding studies: a tutorial. Clinical Trials: 57-71. &lt;https://doi.org/10.1191/1740774506cn134oa&gt;
</p>


<h3>See Also</h3>

<p><code><a href="#topic+sim3p3">sim3p3</a></code>, <code><a href="#topic+ssim3p3">ssim3p3</a></code>
</p>


<h3>Examples</h3>

<pre><code class='language-R'># Study initialization
data&lt;- CreData(5,c("5 mg/m2","7 mg/m2","10 mg/m2","15 mg/m2","20 mg/m2"))
data

# Three patients are treated at the dose 1, without any observed DLT:
data&lt;- updata(data,lastdose=1,npt=3,ndlt=0)
data

# 3+3 design
troisPtrois(data,lastdose=1)
</code></pre>

<hr>
<h2 id='updata'>
Update the CRM dataframe after new patients' collected data
</h2><span id='topic+updata'></span>

<h3>Description</h3>

<p>This function uptdates the CRM dataframe (result of the CreData routine) with new treated patients or observed DLTs.
</p>


<h3>Usage</h3>

<pre><code class='language-R'>updata(data = data, lastdose, npt, ndlt)
</code></pre>


<h3>Arguments</h3>

<table role = "presentation">
<tr><td><code id="updata_+3A_data">data</code></td>
<td>

<p>Dataframe to be updated.
</p>
</td></tr>
<tr><td><code id="updata_+3A_lastdose">lastdose</code></td>
<td>

<p>Integer representing the dose to be updated.
</p>
</td></tr>
<tr><td><code id="updata_+3A_npt">npt</code></td>
<td>

<p>Number of new treated patients.
</p>
</td></tr>
<tr><td><code id="updata_+3A_ndlt">ndlt</code></td>
<td>

<p>Number of DLTs among the npt patients.
</p>
</td></tr>
</table>


<h3>Value</h3>

<p>Updated dataframe.
</p>


<h3>Author(s)</h3>

<p>Benjamin Esterni, Baboukar Mane. Unite de Biostatistique et de Methodologie, Institut Paoli-Calmettes, Marseille, France.
</p>


<h3>References</h3>

<p>O'Quigley J., Pepe M., Fisher L. (1990). Continual Reassessment Method: a practical design for Phase I clinical trials in cancer. Biometrics 46, 33-48. &lt;https://doi.org/10.2307/2531628&gt;
</p>
<p>O'Quigley J., Shen LZ. (1996). Continual Reassessment Method: a likelihood approach. Biometrics 52, 673-684. &lt;https://doi.org/10.2307/2532905&gt;
</p>
<p>Paoletti X., Kramar A. (2009). A comparison of model choices for the Continual Reassessment Method in phase I cancer trials. Statistics in Medecine 28, 3012-3028. &lt;https://doi.org/10.1002/sim.3682&gt;
</p>
<p>Chamorey Emmanuel. (2009). Methodologie des essais de phase precoce en cancerologie: evolution des schemas et apport de la pharmacologie. These.
</p>
<p>Garret-Mayer Elizabeth. (2006). The Continual Reassessment Method for dose-finding studies: a tutorial. Clinical Trials: 57-71. &lt;https://doi.org/10.1191/1740774506cn134oa&gt;
</p>


<h3>See Also</h3>

<p><code><a href="#topic+CreData">CreData</a></code>
</p>


<h3>Examples</h3>

<pre><code class='language-R'># Study initialization
data&lt;- CreData(5,c("5 mg/m2","7 mg/m2","10 mg/m2","15 mg/m2","20 mg/m2"))
data

# Three patients are treated at the dose 1, without any observed DLT:
data&lt;- updata(data,lastdose=1,npt=3,ndlt=0)
data
</code></pre>

</main>

</div>
<script src="https://cdnjs.cloudflare.com/ajax/libs/prism/1.29.0/prism.min.js"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/prism/1.29.0/components/prism-r.min.js"></script>
</body></html>
